Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TDO2 | P48775 | 2/20 | 0.52 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215809 | 0.88 | L3MBTL1 (0.57) | L3MBTL1GLATDO2IDO2POLB | |
| SCHEMBL6216663 | 0.85 | TDO2 (0.48) | TDO2IDO2 | |
| SCHEMBL6214049 | 0.84 | L3MBTL1 (0.62) | L3MBTL1GLATDO2IDO2 | |
| Water SCHEMBL6217170 | 0.84 | TDO2 (0.47) | TDO2IDO2 | |
| SCHEMBL6214054 | 0.83 | DHODH (0.48) | TDO2IDO2DHODH | |
| SCHEMBL6602737 | 0.82 | L3MBTL1 (0.74) | L3MBTL1GLATDO2IDO2POLB | |
| SCHEMBL6621012 | 0.81 | TP53 (0.56) | — | |
| SCHEMBL6601051 | 0.81 | ALDH1A1 (0.70) | L3MBTL1GLATDO2IDO2POLB | |
| SCHEMBL6217521 | 0.81 | — | — | |
| SCHEMBL6217516 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884310-B1 | Quinazolin-4-one ampa antagonists | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6921764-B2 | Thieno-pyrimidin-4-one AMPA antagonists | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6627755-B1 | Neurodegenerative, psychological, and nervous system disorder; drug abuse, alcoholism | PFIZER INC | 2003-09-30 | — | — | US | disclosed |
| EP-0884316-B1 | Quinazoline-4-one AMPA antagonists | PFIZER PROD INC (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6060479-A | Quinazoline-4-one AMPA antagonists | PFIZER INC (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0884316-A1 | Quinazoline-4-one AMPA antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0884310-A1 | Quinazolin-4-one ampa antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | GRIN1, GRIK1, GRIN3A | L3MBTL1 3272/4885GLA 4558/4885TDO2 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.